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doi:10.1016/j.jtcvs.2006.01.064bjectives: We sought to evaluate the effectiveness of tranexamic acid in off-pump
oronary artery bypass grafting surgery, either when used in combination with
echanical cell salvage or when used alone.
ethods: One hundred patients were randomized to either 2 g of tranexamic acid as
n intravenous bolus before sternotomy or to placebo. Intraoperative and postoper-
tive cell salvage was used in all patients. The primary end point was early
ostoperative blood loss (within 4 hours). To evaluate the efficacy of tranexamic
cid in isolation, we also performed a meta-analysis of 4 randomized trials identified
rom a systematic literature search. The primary end point of the meta-analysis was
ed cell transfusion.
esults: In our randomized trial patients in the tranexamic acid group had a
ignificant reduction in early postoperative blood loss, (median difference, 50 mL;
5% confidence interval, 15-100 mL; P  .01); however, there was no reduction in
he frequency of blood component transfusion. Patients in the placebo group
eceived a significantly larger volume of autotransfused red cells (median differ-
nce, 120 mL; 95% confidence interval, 0-220 mL; P  .02). The meta-analysis
emonstrated a significant reduction in red cell transfusions in patients receiving
ranexamic acid compared with those receiving placebo (risk ratio, 0.48; 95%
onfidence interval, 0.24-0.97; P  .041). There was also a reduction in the
requency of any allogeneic blood component transfusion, as well as a highly
ignificant reduction in postoperative blood loss, in patients receiving tranexamic
cid (P  .001).
onclusions: Tranexamic acid reduces blood loss and transfusion requirements in
ff-pump coronary artery bypass grafting surgery. A reduction in allogeneic blood
ransfusion was not evident in the presence of perioperative cell salvage. These data
upport the routine use of tranexamic acid in off-pump coronary artery bypass
rafting surgery.
he evidence base for the development of multimodality blood conservation
protocols that minimize transfusion risk is incomplete. Transfusion of blood
components increase health care costs both directly through the use of an
ncreasingly scarce commodity and indirectly because of transfusion-associated
orbidity attributed to immunosuppression, end-organ dysfunction, and the better-
nown but rare complications, such as viral transmission.1-3 Off-pump coronary
rtery bypass grafting (OPCAB) surgery has been shown in a meta-analysis of
andomized trials4 to reduce the need for allogeneic blood component transfu
ompared with conventional coronary artery bypass grafting (CABG); however, up
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CSPo a quarter of patients in OPCAB studies5-7 till receive 
ransfusion. We have previously demonstrated that mech
cal cell salvage and autotransfusion reduces allogen
lood transfusion rates in OPCAB surgery.8 There is also
vidence from several small randomized trials that tran
mic acid might reduce postoperative blood loss in OPC
urgery.9-12 The aim of the present randomized trial wa
ssess whether the combination of perioperative mechan
ell salvage plus the antifibrinolytic agent tranexamic 
esults primarily in a significant reduction in postopera
lood loss and secondarily in a reduction in transfu
equirements compared with perioperative cell salvage p
lacebo in patients undergoing OPCAB surgery. We 
ought to establish whether the observed reductions in b
oss associated with tranexamic acid use translates in
eduction in red cell transfusions in a larger cohor
erforming a meta-analysis of randomized trials that e
ated the efficacy of tranexamic acid alone versus pla
n OPCAB surgery.
atients and Methods
tudy Population and Patient Allocation
f 153 consecutive patients undergoing isolated OPCAB surg
t the Clinica Montevergine, Mercogliano, Avellino, Italy, ov
-month period, 100 patients consented to enrollment in the s
6 refused consent, and a further 27 were judged unsui
ccording to the inclusion-exclusion criteria. Inclusion crite
ere any male or female patients aged 18 years or older wh
ndergoing nonemergency first-time OPCAB surgery. Exclusi
riteria included advanced chronic renal insufficiency (creatin
2 mg/dL, n  12), active chronic hepatitis or cirrhosis (n  8),
eurologic dysfunction (n  4), and hematologic disorders (n 
). Patients treated with aspirin or heparin, but not clopid
n  5), before the operation were enrolled (some patients 
ore than one exclusion criteria). The study received local e
ommittee approval. Patients were assigned in a 1:1 ratio 
ouble-blind fashion to one of 2 randomized groups: a treat
roup (50 patients) who received tranexamic acid as a bolus 
ver 20 minutes after the induction of anesthesia but before
ncision and a placebo control group (50 patients) who recei
olus of saline. Allocations were generated by a card system
oncealed in sealed opaque envelopes. Both the staff of the 
ting room and that of the intensive care unit (ICU) were b
egarding the treatment by the use of identical unmarked syr
or drug or placebo administration. The primary end point fo
tudy was early postoperative blood loss (within 4 hours posto
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
CI  confidence interval
ICU  intensive care unit
OPCAB off-pump coronary artery bypass graftingively). Given that mean blood loss 4 hours after OPCAB surgeryp
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a
g
a
-
d
e
s approximately 250 mL (standard deviation, 120 mL),9-12 this
tudy was powered to detect a 30% reduction in early bloo
ie, a mean difference of 75 mL) with an  value of .05 and 
ower of 0.8. Secondary end points included total blood 
efined as blood loss at the time of drain removal, frequency 
ell transfusion, and frequency of any blood component tran
ion. This, as well as clinical outcome data, were collected
pectively on preprinted leaflets and transferred to a computer
atabase (Microsoft Access 2003; Microsoft Corp, Seattle, Wa
perative Technique
he anesthetic technique, including heparin dose (150 IU/kg), t
ctivated clotting time of greater than 300 seconds, and prota
ose (1:1 ratio), was standardized for all patients and has 
eported previously.13 The method of exposure and stabilizati
sed to perform the anastomoses has been described previous14
he target vessel was snared proximally before arteriotomy, an
ntracoronary shunt (Anastoflo Intravascular Shunt; Resear
edical Inc, Midvale, Utah) was used to perform each anast
is to reduce blood loss.14 No patient had predonated autologo
lood for use perioperatively. All patients underwent periopera
ell salvage (Fresenius C.A.T.S Continuous AutoTransfusion S
em; Fresenius Kabi Ltd, Warrington, United Kingdom) with
otransfusion of washed salvaged red cells at the completion o
perative procedure. After closure of the sternum, postopera
ediastinal drainage was achieved with 28F single-lumen r
ump drains (1-3 in number) to a 1000-mL sterile colle
hamber connected to 20 cm H2O wall suction through an und-
ater seal, from which subsequent shed mediastinal fluid loss
hen recorded. In accordance with unit protocols, where suffi
ediastinal loss occurred in any patient (400 mL), the shed flu
as processed and washed, and shed cells were autotransfuse
 hours postoperatively or sooner in the event of heavier 
oss. Chest drains were removed when bleeding was less than
L in the preceding 4 hours.
llogeneic Blood Component Transfusion
erioperatively, all patients were administered homologous pac
ed cells as blood replacement therapy, according to predefi
nit protocols. The threshold for transfusion of homologous b
as a hemoglobin concentration of less than 8.5 g/dL or a h
crit value of less than 0.25. As part of routine postoperative care,
aemoglobin concentration and hematocrit value were measured
n arrival in the ICU and then at 2-hour intervals or as clinically
ndicated through the indwelling arterial cannula. In patients with
xcessive blood loss and cardiovascular instability, packed red
ells were given at the discretion of anesthetic or ICU staff.
lotting products and platelets were administered at the discretion
f the ICU staff in response to bleeding in the presence of coagu-
opathy or diminished platelet count. We also performed a com-
arison of hematologic and clotting pathway parameters in the
ostoperative period (Appendix E1).
eta-analysis
he MEDLINE and PubMed databases (1966 through November
004) were searched by using the medical subject headings for
Coronary artery bypass” or the text words “OPCAB” or “off
ump” or “beating heart” or “randomized controlled trial” or
mber 2006
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Pcoronary arteriosclerosis” or “myocardial revascularization”
ombined with the text words “tranexamic acid” or “hemostatics”
r “antifibrinolytic agents.” In addition, the reference lists from
elevant articles, abstracts, and reviews were also searched for
dditional trials. Study selection was as described in Figure E9-12
tudies were assessed and selected by a single observer (GJM) if
hey met the following criteria: (1) comparison of tranexamic acid
ith placebo; (2) patients undergoing OPCAB surgery; (3) pro-
pective randomized controlled methodology; and (4) reporting of
ostoperative transfusion rates and postoperative blood loss. This
dentified 3 studies.9-11 The primary end point for analysis was 
requency of red cell transfusion. Where these data were miss-
ng,11 authors of the study were contacted individually to pro
issing data (Table E1). This correspondence also resulted in
dentification of a further randomized trial before its publication.
his has subsequently been published.12 A scoring system was n
sed, and all 4 studies were entered into the meta-analysis. Sec-
ndary end points included frequency of any blood component
ransfusion (early and total blood loss [reported in milliliters]) and
he frequency of thromboembolic complications (venous throm-
osis, thromboembolism, myocardial infarction, or stroke). In one
tudy9 data on the total number of patients receiving any blood
roduct were missing, and in this case the figures for the total
umber of patients receiving red cells were used in the meta-
nalysis. In 2 of the randomized trials9,12 data were extracted from
tudies in which tranexamic acid versus placebo in OPCAB sur-
ery comprised 2 of a total of 312 or 49 randomized groups,
espectively. The thresholds for allogeneic blood transfusion were
roadly similar in all of the studies (hemoglobin, 8-8.5 g/dL), and
he dose of tranexamic acid administered was the same, a 1-g bolus
t anesthetic induction followed by a continuous infusion of 400
g/h. Data from the present randomized trial were not included
ecause of the significant differences in methodology, such as the
se of cell salvage, that were likely to interact with the primary
utcome.
tatistical Analysis
ontinuous measurements were assessed for normality of distri-
ution. If skewed, data are summarized as a median and interquar-
ile range; otherwise, a mean and standard deviation are given.
ata for the 2 groups were compared by using the Mann-Whitney
est, and effect sizes are expressed as a median difference or hazard
atio (time measurements). Categoric data were reported as the
umber and percentage and were compared by using the Pearson
2 test or the Fisher exact test (if expected frequencies were 5),
nd the odds ratio was used to quantify the effect of tranexamic
cid for binary variables. Hazard ratios were used to quantify
ffect sizes for time to event variables. All effect sizes are reported
ith 95% confidence intervals (CIs).
Meta-analysis was used to combine results from trials examin-
ng the effect of tranexamic acid on outcome. A fixed-effects
odel was chosen because only 4 trials were found. Study results
ere combined by using the Mantel-Haenszel method (transfusion
equirement) or the inverse variance method (blood loss). Blood
oss followed a skewed distribution and was transformed to the
ogarithmic scale for analysis. Results are presented as a risk ratio
transfusion requirement) or as a standardized mean difference
ln[blood loss]). Heterogeneity between studies was assessed by i
The Journal of Thoracicsing the 2 test. Data analysis was performed with SPSS for
indows, Version 9.0 (Chicago, Ill) and SAS version 8.2 (SAS
nstitute, Inc, Cary, NC; mixed regression models) and Stata,
ersion 8.2 (Stata Corporation, College Station, Tex) (meta-anal-
sis) software packages. No correction was made for the number
f outcomes compared. Our interpretation of the findings is based
n the consistency of the findings and their magnitude, as well as
heir statistical significance.
esults
andomized Trial of Tranexamic Acid Versus Placebo
n OPCAB Surgery
reoperative and operative characteristics are shown in
able E2. The 2 groups were balanced preoperatively 
espect to demographics and comorbidity, except for a
igher proportion of triple-vessel disease in the tranexamic
cid group (82% vs 62%, P  .026), although the number
f grafts performed was similar. EuroSCOREs were similar
or the 2 groups (P  .20, Table E2). Intraoperative cha
cteristics were also well matched, apart from a longer
edian operation time in the placebo group (median, 240
interquartile range, 205-270] vs 210 [interquartile range,
80-240]; P  .002). No patients were withdrawn from the
tudy, and there was no crossover between the groups.
There was a significant reduction in blood loss at 4 hours
n the patients receiving tranexamic acid compared with
hose receiving placebo (median difference, 50 mL; 95%
I, 15-100 mL; P  .01); however, there was no difference
n total blood loss (Table 1). There was no difference 
requency of allogeneic red cell or other blood component
ransfusion (odds ratio [tranexamic acid vs placebo], 0.90;
5% CI, 0.37-2.19; P  .82). There was no difference
etween the groups in the frequency of salvaged red cell
utotransfusion; however, the median volume of cells auto-
ransfused was significantly higher in the placebo group
median difference, 120 mL; 95% CI, 0-220 mL; P  .02).
entilation time, ICU stay, hospital stay, and the frequency
f serious morbidity were similar across the groups (T
). There was no difference in the level of postoper
emodilution between the groups (Table 1). There was
tatistically significant difference between the groups at any
ime point for hematocrit value, platelet count, serum cre-
tinine level, serum fibrinogen level, or tests of coagulation
athway function (Table E3).
eta-analysis of 4 Randomized Trials of Tranexamic
cid Versus Placebo in OPCAB Surgery
he meta-analysis included a total of 153 patients (T
1)9-12 and demonstrated a significant reduction in the -
uency of exposure to red cell transfusion (risk ratio, 0.48;
5% CI, 0.24-0.97; P  .041) in patients receiving tranex-
mic acid versus placebo (Figure 1).9-12 Analysis of sec-
ndary end points also demonstrated a significant reduction
n the transfusion of any allogeneic blood component (risk
and Cardiovascular Surgery ● Volume 132, Number 3 477
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CSPatio, 0.50; 95% CI, 0.26-0.94; P  .032; Figure E2). Th
tandardized mean difference for ln(blood loss) for tranex-
mic acid versus placebo at 4 hours was 1.72 (95% CI,
2.05 to 1.39; Figure E3). There was evidence to sug
eterogeneity between studies for blood loss (P  .041).
he zero frequency of thromboembolic events in some of
he studies did not permit a meta-analysis of these data
Table E1).
iscussion
he main finding of our randomized controlled trial was that
ranexamic acid, when used in combination with perioper-
tive cell salvage, results in a significant reduction in early
lood loss after OPCAB surgery. There was no difference in
he frequency of allogeneic blood component transfusion
etween the groups. The meta-analysis of randomized trials
omparing tranexamic acid with placebo in OPCAB surgery
emonstrated a significant reduction in transfusion risk in
atients receiving tranexamic acid versus placebo, as well as
onfirming a significant reduction in postoperative blood
ABLE 1. Postoperative outcome and homologous blood p
utcome Placebo (n  50)
Tranexam
(n 
omologous RBC transfusion 14 (28%) 13 (26%)
o. of units
1 11 (22%) 10 (20%)
2 3 (6%) 1 (2%)
3 0 1 (2%)
4 0 1 (2%)
Total 17 19
latelets–clotting products 0 0
rainage, 4 h (mL) 225 (175 to 350) 175 (100 t
rainage, total (mL) 460 (325 to 625) 390 (300 t
ostoperative cell salvage 31 (62%) 23 (46%)
o. of patients autotransfused 13 (26%) 12 (24%)
olume autotransfused (mL) 400 (300 to 520) 300 (90 to
luid infused, 24 h (mL) 2325 (1490 to 3000) 2500 (1681
n-hospital deaths 0 0
entilation time (h) 9.0 (8.0 to 12.0) 9.0 (8.0 to
ntensive therapy unit stay (d) 1.0 (1.0 to 2.0) 1.0 (1.0 to
otal hospital stay (d) 6.0 (6.0 to 7.0) 6.0 (5.0 to
ostoperative inotropic support 7 (14%) 8 (16%)
ostoperative vasodilators 9 (18%) 7 (14%)
esternotomy 0 1 (2%)
rrhythmia 6 (12%) 2 (4%)
ulmonary complication 0 0
troke 0 0
nfective complication 1 (3%) 2 (7%)
enal complication 0 1 (2%)
yocardial infarction 1 (2%) 0
ne unit of packed (hematocrit value, 0.6) homologous red cells is approx
ells.oss with tranexamic acid. o
78 The Journal of Thoracic and Cardiovascular Surgery ● SepteSeveral observations should be considered when review-
ng these results; first, in the randomized trial there was a
onger operation time in the placebo group, despite similar
umbers of bypass grafts between the groups. Prolonged
perating times in CABG surgery are associated with
reater blood loss and subsequently with blood transfu-
ion.15 We also cannot discount that this time differe
ould have been attributable to more bleeding from the
perative field, with longer closing times in the placebo
roup. The magnitude of the time difference was small,
owever, and there was no difference between the groups
ith regard to the decrease in hematocrit values between
reoperative and immediate postoperative values. We there-
ore consider it unlikely that this affected our results. Sec-
nd, median reduction in blood loss in the tranexamic acid
roup was 50 mL, which suggests a small treatment effect.
hen one also considers that the median difference in
utotransfusion volumes was 120 mL, or approximately half
unit of packed leukodepleted red cells, (patients with only
mall volume losses over 6 hours were not autotransfused),
ct requirements
id Median difference (95% CI),
placebo-autotransfusion
Odds ratio/hazard ratio
(95% CI) P value
0.90 (0.37 to 2.19) .82
) 50 (15 to 100) .01
) 45 (30 to 125) .30
0.52 (0.23 to 1.16) .11
0.90 (0.36 to 2.22) .82
120 (0 to 220) .02
50) 130 (563 to 265) .60
) 0.86 (0.58 to 1.23) .46
1.05 (0.71 to 1.56) .81
0.99 (0.66 to 1.48) .95
1.17 (0.39 to 3.52) .78
0.74 (0.25 to 2.17) .59
.99
0.31 (0.06 to 1.59) .26
2.14 (0.18 to 25.0) .61
.99
.99
ly 280 mL. CI, Confidence interval; RBC, leukodepleted packed red bloodrodu
ic ac
50)
o 250
o 600
400)
to 29
11.3
2.0)
6.0)
imatene can surmise that the treatment effect might be more
mber 2006
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Plinically significant than this figure suggests, however. By
xtrapolating from pharmacokinetic studies in patients under-
oing conventional CABG,16 this 2-g bolus dose, approx-
ately 25 mg/kg per patient, should be sufficient to inhibit
brinolysis in vitro; however, when one considers that the
ffective half-life of tranexamic acid in patients with normal
enal function is approximately 2 hours,17 this effect migh
ot be sustained.16 It is noteworthy that total blood loss 
ot different between treatment and placebo in the current
tudy, unlike those studies cited in the meta-analysis,9-12 in
hich an infusion was maintained intraoperatively. Al-
hough our data suggest that that higher blood loss in the
lacebo group was counterbalanced by larger autotransfu-
ions, resulting in equivalent rates of allogeneic transfusion,
e cannot exclude the possibility that a larger tranexamic
cid dose or an intraoperative infusion might have produced
different result. Third, the randomized study presented
ere excluded many high-risk patients and is not absolutely
epresentative of the patient population at this institution.
imilar criticisms can be made of the studies incorporated
nto the meta-analysis, where the cohorts recruited appeared
o have generally low transfusion risks (few female subjects,
elatively high mean body mass, and young patients with
ood ventricles undergoing nonemergency operations).
hether the observations made either in our randomized
rial or in the meta-analysis would also apply in higher-risk
ases cannot be extrapolated from these data. Another lim-
tation of the meta-analysis is the small sample size. As well
s limiting the power of our observations, it also prevents us
rom commenting on the safety of tranexamic acid in this
Risk ratio
.075153 1 13.30
Study
anek at al (12)
asati et al (9)
asati et al (10)
arem et al (11)
verall (95% CI)etting, given the relative rarity of thromboembolic compli- p
The Journal of Thoracications. We have previously calculated that any clinical
tudy powered to detect a significant reduction (10%) in the
requency of allogeneic blood exposure in our OPCAB
ractice (overall allogeneic transfusion rate, 23%; power,
.9;  value, 0.05) would require more than 600 patien8
his meta-analysis therefore represents the best available
vidence to date supporting the efficacy of tranexamic acid
n OPCAB surgery. Finally, in the meta-analysis there 
eterogeneity between the studies for postoperative blood
oss. This can be attributed to different transfusion risks
mong cohorts in different trials. For example preoperative
spirin within 5 days of the operation, a recognized risk
actor for postoperative bleeding and blood transfusion18
aried from approximately 25% in one study to 47% in
nother.9,11 That this did not translate into heterogene
etween the trials for blood transfusion rates presumably
eflects the large differences in blood loss required to alter
ransfusion rates.
In conclusion, we have previously demonstrated a
eduction in postoperative blood loss with the use of
echanical cell salvage in OPCAB surgery. The meta-
nalysis presented here demonstrates a significant reduc-
ion in blood transfusion rates when tranexamic acid is
sed in isolation. Our randomized trial suggests that
ranexamic acid reduces blood loss when combined with
erioperative cell salvage; however, there is no reduction
n the frequency of allogeneic transfusion. Larger trials
re required to confirm these findings and develop more
omprehensive multimodality protocols for reducing ex-
% Weight
ratio
 CI)
0.13,1.71) 29.7
0.18,2.90) 19.6
0.10,2.43) 19.2
0.08,1.40) 31.5
0.24,0.97)
Figure 1. Effect of tranex-
amic acid on red cell trans-
fusion after OPCAB surgery.
Tranexamic acid signifi-
cantly reduced red cell trans-
fusion. There was no evi-
dence of heterogeneity
between the studies (hetero-
geneity test, 0.61; P  .90).
95% CI, 95% confidence inter-
val.62
Risk 
(95%
0.47 (
0.72 (
0.50 (
0.32 (
0.48 (osure to allogeneic blood products.
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Pppendix E1
aboratory Measurements of Clotting Pathway Function
easurement of hematocrit values, platelet counts, clotting pathway
unction (prothrombin time and international normalized ratio of the
rothrombin time, measurement of the extrinsic and common clotting
athways, and measurement of activated partial thromboplastin time
xpressed as the activated partial thromboplastin time ratio to a
ormalized control value, a measure of the intrinsic and common
lotting pathways), and serum fibrinogen levels were performed pre-
peratively, immediately postoperatively on admission to the ICU,
nd then at 24 and 48 hours postoperatively.
tatistical Analysis
Postoperative measurements of hematocrit values, plateletount, clotting parameters, and renal function were compared by m
The Journal of Thoracic asing a mixed regression model, with adjustment for preoperative
eadings. A variety of models describing the correlation between
epeated measurements on the same patient were examined, and
he structure leading to the lowest value for the Schwarz’s Bayes-
an information criterion was chosen in each case. Creatinine
easurements followed a skewed distribution and were trans-
ormed to the logarithmic scale for analysis. Changes in treat-
ent effect over time were assessed by using the F test, and if
tatistically significant at the 10% level, the treatment differ-
nce is reported separately at each time point; otherwise, an overall
ffect of treatment is given (estimate of common difference).
esults are presented as least squares means and as difference
etween means with 95% confidence intervals. Creatinine results
re presented as geometric means and as a ratio of geometric
eans.
nd Cardiovascular Surgery ● Volume 132, Number 3 480.e1
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CSPSearch Criteria
MEDLINE and PubMed databases (1966 through November 2004)  search 
[(“Coronary artery bypass” (MeSH) ” OR text words: “OPCAB” OR “off pump” 
OR “beating heart” OR “Randomised Controlled Trial” “ OR “Coronary 
arteriosclerosis” OR “myocardial revascularisation”) AND (text words: 
“tranexamic acid” OR “haemostatics”, OR “antifibrinolytic agents”)].
809 Publications
Limited to Clinical trials, case series, case reports and meta-analyses, n=523
Limited to Cardiac Surgery n=339 
Limited to studies including OPCAB surgery n=13
Selection Criteria
1) Comparison of tranexamic acid with placebo
2) Patients undergoing OPCAB surgery
3) Prospective randomised controlled methodology
4) Reporting of postoperative transfusion rates and postoperative blood loss. 
3 Publications identified
Authors approached for missing data
Further randomised trial identified pre publication after personal 
communication from authors; meets selection criteria
4 studies submitted for meta-analysis
Figure E1. Systematic literature search and study
selection for meta-analysis. OPCAB, Off-pump cor-
onary artery bypass grafting.80.e2 The Journal of Thoracic and Cardiovascular Surgery ● September 2006
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PRisk ratio
.075153 1 13.3062
Study % Weight
Risk ratio
(95% CI)
0.52 (0.20,1.38)Vanek et al (12) 38.8
0.72 (0.18,2.90)Casati et al (9) 17.0
0.50 (0.10,2.43)Casati et al (10) 16.7
0.32 (0.08,1.40)Jarem et al (11) 27.4
0.50 (0.26,0.94)Overall (95% CI)
Figure E2. Effect of tranexamic acid on the frequency of any blood component transfusion after off-pump coronary
artery bypass grafting surgery. Tranexamic acid significantly reduced exposure to any allogeneic blood product
(heterogeneity test, 0.61; P  .895). CI, Confidence interval.The Journal of Thoracic and Cardiovascular Surgery ● Volume 132, Number 3 480.e3
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CSPStandardised Mean diff.
-3.42622 0 3.42622
Study % Weight
Standardised Mean diff.
(95% CI)
-1.22 (-1.76,-0.68)Vanek et al (12) 36.8
-1.62 (-2.26,-0.99)Casati et al (9) 26.9
-2.58 (-3.43,-1.73)Casati et al (10) 15.1
-2.08 (-2.80,-1.37)Jarem et al (11) 21.2
-1.72 (-2.05,-1.39)Overall (95% CI)
Figure E3. Effect of tranexamic acid on 4-hour blood loss after off-pump coronary artery bypass grafting surgery.
Distributions for blood loss followed a skewed distribution and were transformed to the logarithmic scale for
meta-analysis. Values represent the standardized mean difference (ln[blood loss]) for tranexamic acid versus
placebo. There was evidence to suggest heterogeneity between studies (heterogeneity test, 8.23; P  .041). CI,
Confidence interval.80.e4 The Journal of Thoracic and Cardiovascular Surgery ● September 2006
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PABLE E1. Summary of randomized trials of tranexamic acid versus placebo in OPCAB surgery
Total no. of patients No. transfused
No. transfused RBC
only
Units of RBC
transfused
Placebo TA Placebo TA Placebo TA Placebo TA
anek and coworkers12 30 32 9 5 6 3 14 6
asati and coworkers10 25 26 4 3 11 6
asati and coworkers9 20 20 4 2 4 2 11 4
ares and coworkers11 25 22 7 2 7 2 16 6
BC, Leukodepleted packed red blood cells; IQR, interquartile range; TA, tranexamic acid.The Journal of Thoracic and Cardiovascular Surgery ● Volume 132, Number 3 480.e5
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CSPEarly blood loss, median (IQR) 24-h Blood loss, median (IQR)
Thromboembolic
complications
Placebo TA Placebo TA Placebo TA
192.3 (151.8 to 243.5) 89.3 (72.7 to 109.8), geometric mean
(95% CI)
619.8 (524.3 to 732.8) 410.3 (337.6 to 498.6) 0 0
311 (255 to 450) 150 (100 to 190) 654 (510 to 820) 375 (356 to 550) 1 1
375 (295 to 450) 150 (100 to 170) 650 (550 to 875) 400 (338 to 485) 0 0
230 (170 to 260) 115 (92 to 148) 550 (500 to 650) 420 (330 to 523) 1 1
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PABLE E2. Patient characteristics
Variable Placebo (n  50) Tranexamic acid (n  50)
Age (y) 65.8 (8.7) 64.9 (7.0)
Tranexamic acid dose (mg/kg) 0 26.8 (21.9 to 30.1)
Male sex 37 (74%) 42 (84%)
Body mass index (kg/m2) 28.6 (4.49) 27.3 (4.35)
Diabetes
Diet 0 2 (4%)
Insulin 8 (16%) 6 (12%)
Oral 14 (28%) 17 (34%)
Hypertension 38 (76%) 37 (74%)
Hyperlipidemia 24 (48%) 26 (52%)
Current smoker 11 (22%) 13 (26%)
COPD 15 (30%) 17 (34%)
Baseline serum creatinine (mg/dL) 0.96 (0.85 to 1.05) 1.01 (0.83 to 1.22)
Renal impairment 1 (2%) 5 (10%)
Previous stroke/neurologic dysfunction 1 (2%) 1 (2%)
Peripheral vascular disease 4 (8%) 4 (8%)
Aspirin within 5 d of operation 2 (4%) 1 (2%)
CCS class (angina)
0/1 18 (36%) 16 (32%)
2 22 (44%) 27 (54%)
3 8 (16%) 7 (14%)
4 2 (4%) 0
NYHA score (dyspnea)
I 13 (26%) 13 (26%)
II 30 (60%) 32 (64%)
III 7 (14%) 5 (10%)
MI 1 mo of operation 23 (46%) 24 (48%)
Congestive cardiac failure 2 (4%) 0
Vessels diseased
2 19 (28%) 9 (18%)
3 31 (62%) 41 (82%)
Ejection fraction 30% 2 (4%) 2 (4%)
Urgent 5 (10%) 6 (12%)
Heparin infusion preoperatively 1 (2%) 3 (6%)
EuroSCORE 3.0 (2.0 to 5.0) 4 (2.75 to 6.0)
No. of grafts 3.0 (2.0 to 3.0) 3.0 (2.0 to 3.0)
Intraoperative inotropes 7 (14%) 3 (6%)
Intraoperative vasodilators 16 (32%) 11 (22%)
Operation time (min) 240 (205 to 270) 210 (180 to 240)
alues represent numbers of patient with percentages, except for continuous variables, where values are means (standard deviations) for normally
istributed data and medians (interquartile ranges) for skewed data. COPD, Chronic obstructive pulmonary disease; CCS, Canadian Cardiovascular Society;
YHA, New York Heart Association; MI, myocardial infarction.
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CSPABLE E3. Haemoglobin concentration, platelet count, and measures of clotting pathway and renal function: Response
ver time and effect sizes
ariable
Randomized to tranexamic
acid, mean* (SE)
Randomized to placebo,
mean* (SE) Difference 95% CI P value
CT
Preoperative 39.39 (0.69) 40.25 (0.58)
Postoperative 30.14 (0.40) 29.72 (0.41) 0.42 0.74 to 1.57 .48
24 h 29.14 (0.42) 29.59 (0.37) 0.45 1.57 to 0.67 .43
48 h 26.79 (0.43) 27.89 (0.40) 1.09 2.26 to 0.07 .065
est for common difference P  .036
latelets ( 109/L)
Preoperative 221.7 (9.16) 230.5 (8.94)
Postoperative 168.4 (3.89) 162.1 (3.53) 6.30 4.07 to 16.66 .23
24 h 174.9 (4.33) 166.2 (3.96) 8.78 2.80 to 20.37 .14
48 h 153.3 (4.42) 159.1 (5.33) 5.89 19.44 to 7.85 .40
est for common difference P  .046
reatinine† (mg/dL)
Preoperative 1.08 (1.06) 0.94 (1.03)
Postoperative 0.84 (1.02) 0.82 (1.02) 1.027
24 h 0.94 (1.02) 0.96 (1.02) 0.984
48 h 0.98 (1.02) 0.95 (1.02) 1.032
est for common ratio P  .12
stimate of common ratio 1.014 0.968 to 1.062 .55
PTT
Preoperative 33.18 (0.94) 34.96 (1.22)
Postoperative 36.17 (0.74) 35.25 (0.79) 0.92 1.22 to 3.06 .40
24 h 36.46 (1.01) 37.76 (1.22) 1.30 4.43 to 1.83 .41
48 h 46.00 (1.55) 50.60 (1.84) 4.60 9.32 to 0.12 .056
est for common difference P  .087
T (s)
Preoperative 95.40 (1.10) 95.90 (1.03)
Postoperative 75.09 (1.10) 72.11 (1.19) 2.98
24 h 79.50 (1.02) 78.72 (1.16) 0.78
48 h 82.39 (0.96) 81.06 (0.89) 1.33
est for common difference P  .44
stimate of common difference 1.70 0.59 to 3.98 .14
NR
Preoperative 1.06 (0.012) 1.05 (0.010)
Postoperative 1.27 (0.014) 1.29 (0.012) 0.028
24 h 1.21 (0.012) 1.23 (0.014) 0.021
48 h 1.20 (0.012) 1.21 (0.009) 0.007
est for common difference P  .58
stimate of common difference 0.019 0.045 to 0.007 .15
ibrinogen (g/L)
Preoperative 390.3 (15.9) 406.2 (18.2)
Postoperative 247.9 (6.9) 245.6 (11.3) 2.34
24 h 371.2 (13.1) 372.0 (13.4) 0.73
48 h 573.2 (17.8) 600.0 (18.2) 26.79
est for common difference P  .45
stimate of common difference 8.39 39.52 to 22.73 .59
he F test was used to compare the treatment effect (difference between placebo and tranexamic acid) over time (ie, test of an interaction with time).
f the difference between placebo and tranexamic acid is similar over time, the treatment effect is pooled over the 3 time points to give one overall estimate
f the difference between treatments; otherwise, the effect is reported separately for each time point. There was variation (P  .10) in the magnitude of
he difference (treatment effect) over the 3 postoperative time points for hematocrit value, platelet count, and activated partial thromboplastin time but not
or the other measures. With the possible exception of the hematocrit value and activated partial thromboplastin time at 48 hours (P  .065 and P  .056,
espectively), no significant differences between the 2 groups were found. SE, Standard error; CI, confidence interval; HCT, hematocrit; APTT, activated
artial thromboplastin time; PT, prothrombin time; INR, international normalized ratio. *Means for measurements after surgical intervention are adjusted
or the preoperative value. †Geometric means and ratio of geometric means. SEs have been transformed back to the original measurement scale.
onfidence intervals are calculated as follows: mean/(SE)1.96 to mean  (SE)1.96.
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